Johnson & Johnson (ETR:JNJ)
152.08
+0.66 (0.44%)
Mar 31, 2025, 2:44 PM CET
Johnson & Johnson Revenue
In the year 2024, Johnson & Johnson had annual revenue of $88.82B USD with 4.30% growth. Johnson & Johnson had revenue of $22.52B in the quarter ending December 29, 2024, with 5.26% growth.
Revenue
$88.82B
Revenue Growth
+4.30%
P/S Ratio
n/a
Revenue / Employee
$643.16K
Employees
138,100
Market Cap
364.22B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
Dec 29, 2019 | Pro | Pro | Pro |
Dec 30, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Jan 1, 2017 | Pro | Pro | Pro |
Jan 3, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck KGaA | 21.16B |
Siemens Healthineers AG | 22.67B |
Fresenius SE & Co. KGaA | 21.83B |
Bayer Aktiengesellschaft | 46.61B |
Sartorius Aktiengesellschaft | 3.38B |
Fresenius Medical Care AG | 19.34B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.16B |
Johnson & Johnson News
- 1 day ago - Johnson & Johnson (JNJ) Evaluated Amidst Tariff Talks - GuruFocus
- 2 days ago - If I Could Only Choose 5 Dividend Stocks For My Retirement Portfolio - Seeking Alpha
- 2 days ago - Johnson & Johnson Needs Time To Consolidate (Technical Analysis And Downgrade) - Seeking Alpha
- 2 days ago - Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case - Reuters
- 3 days ago - Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector. - Market Watch
- 4 days ago - Strategically Building A $100,000 Dividend Portfolio For Attractive Income And Strong Risk-Adjusted Returns - Seeking Alpha
- 4 days ago - RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer - PRNewsWire
- 4 days ago - Tech struggles while oil and financials rise: A comprehensive market snapshot - Forexlive